ARS Pharmaceuticals (SPRY) Q4 2025 earnings summary

Executive summary

• neffy, the first FDA- and EC-approved needle-free epinephrine nasal spray, generated $72.2 million in U.S. net product revenue and $84.3 million in total revenue in its first full commercial year, with strong physician engagement and patient uptake despite market challenges.

• Real-world data showed 90% efficacy with a single dose, supporting neffy's safety and reliability.

• Commercial strategy focused on infrastructure, market education, and execution, prioritizing access, adoption, and advancement.

• Over 22,500 healthcare providers prescribed neffy by year-end 2025, with significant adoption in schools and high engagement from allergists and pediatricians.

• Global expansion continued with approvals in China and Australia, and a positive CHMP opinion for EURneffy in Europe.

Financial highlights

• Full year 2025 revenue totaled $84.3 million: $72.2 million U.S. net product revenue, $9.7 million from collaborations, $2.4 million from international supply.

• Q4 2025 revenue was $28.1 million, including $20.3 million from U.S. neffy sales, $6.9 million from international collaborations, and $0.9 million from supply revenue.

• R&D expenses were $13.2 million, mainly for product development and clinical trials.

• SG&A expenses reached $230.1 million, reflecting investments in commercialization and DTC campaigns.

• Year-end 2025 cash, cash equivalents, and short-term investments totaled $245 million.

Outlook and guidance

• 2026 focus is on operational precision, expanding sales force from 106 to 150 through reallocation of commercial resources, with no increase in SG&A run rate.

• Direct-to-consumer and healthcare provider advertising spend in 2026 expected to remain at ~$100 million, consistent with 2025.

• Cash position expected to fund commercial expansion, DTC investment, and pipeline advancement through cash flow breakeven.

• Regulatory approval in Canada is expected in Q2 2026, with launch later in the year.

• Interim data from the Phase 2b urticaria trial is anticipated in the second half of 2026.